Literature DB >> 27222010

Sympathetic neural signaling via the β2-adrenergic receptor suppresses T-cell receptor-mediated human and mouse CD8(+) T-cell effector function.

Leonardo D Estrada1, Didem Ağaç1, J David Farrar1.   

Abstract

Postganglionic sympathetic neurons innervate secondary lymphoid organs and secrete norepinephrine (NE) as the primary neurotransmitter. NE binds and signals through five distinct members of the adrenergic receptor family. In this study, we show elevated expression of the β2-adrenergic receptor (ADRB2) on primary human CD8(+) effector memory T cells. Treatment of both human and murine CD8(+) T cells with NE decreased IFN-γ and TNF-α secretion and suppressed their cytolytic capacity in response to T-cell receptor (TCR) activation. The effects of NE were specifically reversed by β2-specific antagonists. Adrb2(-/-) CD8(+) T cells were completely resistant to the effects of NE. Further, the ADRB2-specific pharmacological ligand, albuterol, significantly suppressed effector functions in both human and mouse CD8(+) T cells. While both TCR activation and stimulation with IL-12 + IL-18 were able to induce inflammatory cytokine secretion, NE failed to suppress IFN-γ secretion in response to IL-12 + IL18. Finally, the long-acting ADRB2-specific agonist, salmeterol, markedly reduced the cytokine secretion capacity of CD8(+) T cells in response to infection with vesicular stomatitis virus. This study reveals a novel intrinsic role for ADRB2 signaling in CD8(+) T-cell function and underscores the novel role this pathway plays in adaptive T-cell responses to infection.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD8+ T cells; Cytokine; Cytolysis; Norepinephrine; β2-Adrenergic receptor

Mesh:

Substances:

Year:  2016        PMID: 27222010      PMCID: PMC5241047          DOI: 10.1002/eji.201646395

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  45 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The level of IgE produced by a B cell is regulated by norepinephrine in a p38 MAPK- and CD23-dependent manner.

Authors:  Georg Pongratz; Jaclyn W McAlees; Daniel H Conrad; Robert S Erbe; Karen M Haas; Virginia M Sanders
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

3.  α7 nicotinic acetylcholine receptor signaling inhibits inflammasome activation by preventing mitochondrial DNA release.

Authors:  Ben Lu; Kevin Kwan; Yaakov A Levine; Peder S Olofsson; Huan Yang; Jianhua Li; Sonia Joshi; Haichao Wang; Ulf Andersson; Sangeeta S Chavan; Kevin J Tracey
Journal:  Mol Med       Date:  2014-08-14       Impact factor: 6.354

4.  Stimulation of the B cell receptor, CD86 (B7-2), and the beta 2-adrenergic receptor intrinsically modulates the level of IgG1 and IgE produced per B cell.

Authors:  D J Kasprowicz; A P Kohm; M T Berton; A J Chruscinski; A Sharpe; V M Sanders
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

5.  Adaptive immunity in mice lacking the beta(2)-adrenergic receptor.

Authors:  Virginia M Sanders; Deborah J Kasprowicz; Michelle A Swanson-Mungerson; Joseph R Podojil; Adam P Kohm
Journal:  Brain Behav Immun       Date:  2003-02       Impact factor: 7.217

6.  Reciprocal responsiveness to interleukin-12 and interferon-alpha specifies human CD8+ effector versus central memory T-cell fates.

Authors:  Hilario J Ramos; Ann M Davis; Alexander G Cole; John D Schatzle; James Forman; J David Farrar
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

7.  Activated T helper 1 and T helper 2 cells differentially express the beta-2-adrenergic receptor: a mechanism for selective modulation of T helper 1 cell cytokine production.

Authors:  D S Ramer-Quinn; R A Baker; V M Sanders
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

8.  Differential effects of beta2-adrenoceptor desensitization on the IgE-dependent release of chemical mediators from cultured human mast cells.

Authors:  Toshikazu Tsuji; Toshinobu Kato; Masahiro Kimata; Toru Miura; Isao Serizawa; Naoki Inagaki; Hiroichi Nagai
Journal:  Biol Pharm Bull       Date:  2004-10       Impact factor: 2.233

9.  Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells.

Authors:  D Lo; J Freedman; S Hesse; R D Palmiter; R L Brinster; L A Sherman
Journal:  Eur J Immunol       Date:  1992-04       Impact factor: 5.532

10.  An interleukin-1 beta-induced noradrenaline release in the spleen is mediated by brain corticotropin-releasing factor: an in vivo microdialysis study in conscious rats.

Authors:  N Shimizu; T Hori; H Nakane
Journal:  Brain Behav Immun       Date:  1994-03       Impact factor: 7.217

View more
  28 in total

1.  The β2-adrenergic receptor controls inflammation by driving rapid IL-10 secretion.

Authors:  Didem Ağaç; Leonardo D Estrada; Robert Maples; Lora V Hooper; J David Farrar
Journal:  Brain Behav Immun       Date:  2018-09-05       Impact factor: 7.217

2.  Neurotransmitter signalling via NMDA receptors leads to decreased T helper type 1-like and enhanced T helper type 2-like immune balance in humans.

Authors:  Kanami Orihara; Solomon O Odemuyiwa; William P Stefura; Ramses Ilarraza; Kent T HayGlass; Redwan Moqbel
Journal:  Immunology       Date:  2017-11-03       Impact factor: 7.397

3.  β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy.

Authors:  Mark J Bucsek; Guanxi Qiao; Cameron R MacDonald; Thejaswini Giridharan; Lauren Evans; Brian Niedzwecki; Haichao Liu; Kathleen M Kokolus; Jason W-L Eng; Michelle N Messmer; Kristopher Attwood; Scott I Abrams; Bonnie L Hylander; Elizabeth A Repasky
Journal:  Cancer Res       Date:  2017-08-17       Impact factor: 12.701

4.  Blockade of Host β2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs.

Authors:  Hemn Mohammadpour; Rachel O'Neil; Jingxin Qiu; Philip L McCarthy; Elizabeth A Repasky; Xuefang Cao
Journal:  J Immunol       Date:  2018-02-14       Impact factor: 5.422

5.  β3 -Adrenoceptor as a potential immuno-suppressor agent in melanoma.

Authors:  Maura Calvani; Gennaro Bruno; Massimo Dal Monte; Romina Nassini; Filippo Fontani; Arianna Casini; Lorenzo Cavallini; Matteo Becatti; Francesca Bianchini; Francesco De Logu; Giulia Forni; Giancarlo la Marca; Lido Calorini; Paola Bagnoli; Paola Chiarugi; Alberto Pupi; Chiara Azzari; Pierangelo Geppetti; Claudio Favre; Luca Filippi
Journal:  Br J Pharmacol       Date:  2019-05-09       Impact factor: 8.739

6.  Mouse T cells express a neurotransmitter-receptor signature that is quantitatively modulated in a subset- and activation-dependent manner.

Authors:  Kenneth M Rosenberg; Nevil J Singh
Journal:  Brain Behav Immun       Date:  2019-04-03       Impact factor: 7.217

7.  Dissecting the role of cell signaling versus CD8+ T cell modulation in propranolol antitumor activity.

Authors:  Wei Li; Jielin Wan; Cuiyu Chen; Chengfang Zhou; Ping Liao; Qian Hu; Jiali Hu; Yang Wang; Yu Zhang; Cong Peng; Yuanfei Huang; Weihua Huang; Wei Zhang; Howard L Mcleod; Yijing He
Journal:  J Mol Med (Berl)       Date:  2022-07-27       Impact factor: 5.606

8.  Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice.

Authors:  Kathleen M Kokolus; Ying Zhang; Jeffrey M Sivik; Carla Schmeck; Junjia Zhu; Elizabeth A Repasky; Joseph J Drabick; Todd D Schell
Journal:  Oncoimmunology       Date:  2017-12-21       Impact factor: 8.110

9.  Destress and do not suppress: targeting adrenergic signaling in tumor immunosuppression.

Authors:  Ignacio Iñigo-Marco; Marta M Alonso
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

Review 10.  Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges.

Authors:  Tin Kyaw; Karlheinz Peter; Yi Li; Peter Tipping; Ban-Hock Toh; Alex Bobik
Journal:  Br J Pharmacol       Date:  2017-06-13       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.